Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 20, 2021 - Issue 4
Submit an article Journal homepage
387
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy

Daniel G. DaunerDepartment of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, MN, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1198-0468View further author information
ORCID Icon &
Joel F. FarleyDepartment of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, MN, USAORCID Iconhttps://orcid.org/0000-0002-5196-5238View further author information
ORCID Icon
Pages 475-480 | Received 23 Sep 2020, Accepted 04 Feb 2021, Published online: 26 Mar 2021

References

  • Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
  • Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020.
  • Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20:889–897.
  • Wang T, Lu W, Tang H, et al. Assessing the association between GLP-1 receptor agonist use and diabetic retinopathy through the FDA adverse event reporting system. Diabetes Care. 2019;43:e21–e23.
  • Peter R, Bain SC. Safety of injectable semaglutide for type 2 diabetes. Expert Opin Drug Saf. 1-13 4 Jun 2020. DOI:10.1080/14740338.2020.1772230
  • Rizzo M, Nikolic D, Di Pace F, et al. GLP-1 receptor agonists, carotid atherosclerosis, and retinopathy. Expert Opin Pharmacother. 2017 Aug;18(12):1163–1165.
  • Fadini GP, Sarangdhar M, Avogaro A. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA adverse event reporting system. BMJ Open Diab Res Care. 2018;6:e000475.
  • Ueda P, Pasternak B, Eliasson B, et al. Glucagon-like peptide 1 receptor agonists and risk of diabetic retinopathy complications: cohort study in nationwide registers from two countries. Diabetes Care. 2019;42:e92–e94.
  • Gaborit B, Julla JB, Besbes S, et al. Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the AngioSafe type 2 diabetes study. J Clin Endocrinol Metab. 2020;105(4):1–12.
  • Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–486.
  • Saxenda [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020.
  • Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
  • Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54:933–941.
  • Dicembrini I, Nreu B, Scatena A, et al. Erratum to: microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54:1069–1071.
  • Wang T, Hong JL, Gower EW, et al. Incretin-based therapies and diabetic retinopathy: real-world evidence in older US adults. Diabetes Care. 2018;41:1998–2009.
  • Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130.
  • Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289:2554–2559.
  • Lauer MS, Topol EJ. Clinical trials-multiple treatments, multiple end points, and multiple lessons. JAMA. 2003;289:2575–2577.
  • Marx N, McGuire DK, Perkovic V, et al. Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point? Diabetes Care. 2017;40:1144–1151.
  • Bain SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2019;21:454–466.
  • US National Library of Medicine. A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS). https://clinicaltrials.gov/ct2/show/NCT03811561. Accessed 2020 Jun 20
  • US Food and Drug Administration. Ozempic (semaglutide). Orange book: approved drug products with therapeutic equivalence evaluations. [cited June 20, 2020]. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=209637#34130
  • Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and the United States food and drug administration’s adverse event reporting system (FAERS): analysis of sixty-two drug approved from 2006-2010. Drug Saf. 2014;37:283–294.
  • Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891–898.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.